Curve Therapeutics
6 known investors
Find your way into Curve Therapeutics
Sign up to see every warm intro you have to Curve Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Curve Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Curve Therapeutics uses its mammalian cell-based Microcycle discovery platform to develop cyclic peptide and small molecule drugs against intracellular targets. Its pipeline focuses on cancer, immunology, and inflammation.
Investors · 6
How we know: Epidarex Capital's portfolio page · southampton.ac.uk · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: southampton.ac.uk · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: southampton.ac.uk · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AMar 2024
Pfizer Ventures (lead), Advent Life Sciences, British Patient Capital, Columbus Venture Partners, Epidarex Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Related companies · 3
Companies working in the same space as Curve Therapeutics.
In the news
Frequently asked questions
- What does Curve Therapeutics do?
- Curve Therapeutics uses its mammalian cell-based Microcycle discovery platform to develop cyclic peptide and small molecule drugs against intracellular targets. Its pipeline focuses on cancer, immunology, and inflammation.
- Who are Curve Therapeutics's investors?
- Curve Therapeutics's investors include Epidarex Capital, Pfizer Venture Investments, Advent Life Sciences, British Patient Capital, Columbus Venture Partners, Pfizer Ventures.



